Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808249 · ClinicalTrials.gov registry record · Phase 2
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
A Phase 2 study of Anxiety Disorders, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 725
- Enrollment target
- 20
- Study locations
NCT00808249: Completed Phase 2 study of Anxiety Disorders, sponsored by AstraZeneca.
NCT00808249 is a Phase 2 study of Anxiety Disorders that has completed, run by AstraZeneca. The registered enrollment target is 725 participants, below the 1,131-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808249, a Phase 2 study of Anxiety Disorders, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 725 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Primary Outcome
The HAM -A is a 14-item clinician administered scale for the evaluation of anxiety symptoms. Each HAM-A item is rated on a 0 (not present) to 4 (very severe) scale, higher score indicates high level of anxiety. The HAM-A total score is calculated as the sum of 14 individual scores, with 56 as the maximum.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD7325
Study Locations (20)
California
- Research Site - Arcadia
- Research Site - Beverly Hills
- Research Site - Cerritos
- Research Site - Chino
- Research Site - Encino
- Research Site - Los Alamitos
- Research Site - Novato
- Research Site - Oceanside
- Research Site - San Diego
Florida
- Research Site - Fort Myers
- Research Site - Miami
- Research Site - Pembroke Pines
- Research Site - Saint Petersberg
- Research Site - Tampa
- Research Site - Winter Park
Georgia
- Research Site - Atlanta
- Research Site - Marietta
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Tucson
Connecticut
- Research Site - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00808249 record still lists
NCT00808249 is an interventional study that assigns participants to a tested intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap, below the 1,131-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00808249 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00808249 about?
NCT00808249 is a clinical study titled "AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)". The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
What is the current status of trial NCT00808249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 725 participants. The study started on 2008-12. Estimated completion is 2009-05.
What conditions does trial NCT00808249 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT00808249?
The interventions under investigation include: Placebo (DRUG), AZD7325 (DRUG).
Who is sponsoring clinical trial NCT00808249?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808249 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00808249's enrollment target sits among peer trials
725 11th of 84 higher than 74 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
-
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
RECRUITING · Phase 2
-
Pramipexole to Enhance Social Connections
RECRUITING · Phase 2
-
Inhaled Oxytocin and HPA Axis Reactivity
COMPLETED · Phase 2
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia